1. Home
  2. IGMS vs SOL Comparison

IGMS vs SOL Comparison

Compare IGMS & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGMS
  • SOL
  • Stock Information
  • Founded
  • IGMS 1993
  • SOL 2005
  • Country
  • IGMS United States
  • SOL United States
  • Employees
  • IGMS N/A
  • SOL N/A
  • Industry
  • IGMS Biotechnology: Pharmaceutical Preparations
  • SOL Semiconductors
  • Sector
  • IGMS Health Care
  • SOL Technology
  • Exchange
  • IGMS Nasdaq
  • SOL Nasdaq
  • Market Cap
  • IGMS 82.1M
  • SOL 84.6M
  • IPO Year
  • IGMS 2019
  • SOL 2008
  • Fundamental
  • Price
  • IGMS $1.24
  • SOL $1.59
  • Analyst Decision
  • IGMS Hold
  • SOL Buy
  • Analyst Count
  • IGMS 8
  • SOL 3
  • Target Price
  • IGMS $6.14
  • SOL $3.50
  • AVG Volume (30 Days)
  • IGMS 198.4K
  • SOL 655.9K
  • Earning Date
  • IGMS 03-06-2025
  • SOL 03-13-2025
  • Dividend Yield
  • IGMS N/A
  • SOL N/A
  • EPS Growth
  • IGMS N/A
  • SOL N/A
  • EPS
  • IGMS N/A
  • SOL N/A
  • Revenue
  • IGMS $2,679,000.00
  • SOL $92,067,000.00
  • Revenue This Year
  • IGMS $134.71
  • SOL $58.47
  • Revenue Next Year
  • IGMS $74.27
  • SOL N/A
  • P/E Ratio
  • IGMS N/A
  • SOL N/A
  • Revenue Growth
  • IGMS 25.77
  • SOL N/A
  • 52 Week Low
  • IGMS $1.15
  • SOL $1.04
  • 52 Week High
  • IGMS $22.50
  • SOL $3.00
  • Technical
  • Relative Strength Index (RSI)
  • IGMS 37.38
  • SOL 48.31
  • Support Level
  • IGMS $1.17
  • SOL $1.62
  • Resistance Level
  • IGMS $1.31
  • SOL $1.73
  • Average True Range (ATR)
  • IGMS 0.09
  • SOL 0.15
  • MACD
  • IGMS 0.05
  • SOL 0.02
  • Stochastic Oscillator
  • IGMS 32.14
  • SOL 72.37

About IGMS IGM Biosciences Inc.

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

About SOL Emeren Group Ltd each representing 10 shares

Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.

Share on Social Networks: